The Impact of GLP-1 Agonists on Bone Density in Menopausal Women

The Impact of GLP-1 Agonists on Bone Density in Menopausal Women and how to protect your bone health

I have no doubt everyone has heard about GLP-1 agonists (glucagon-like peptide-1 receptor agonists), a class of pharmaceutical medications that have revolutionized the treatment of Type 2 diabetes and obesity. These medications, including Ozempic (semaglutide), Saxenda (liraglutide), and others, work by mimicking the action of the natural GLP-1 hormone in the body, which plays a key role in regulating blood sugar levels and appetite. Originally designed to help people with Type 2 diabetes manage blood glucose, these medications also induce significant weight loss, making them highly effective for individuals struggling with obesity, a major risk factor for diabetes and cardiovascular disease.

While GLP-1 agonists offer significant benefits for metabolic health, they are not without controversy. Common side effects, such as nausea, diarrhea, abdominal discomfort, loss of appetite, and dry mouth, are well-documented. Another notable concern that has recently been raised is their potential impact on bone density, particularly in menopausal women.

Menopause and Bone Health

Menopause marks a turning point in a woman’s life, both hormonally and physically. As estrogen levels decline during and after menopause, the rate of bone resorption (the breakdown of bone tissue) often exceeds the rate of bone formation, leading to a gradual loss of bone density. This puts menopausal women at higher risk for osteopenia and osteoporosis.

Understanding the effect of weight-loss medications, including GLP-1 agonists, on bone density is crucial for menopausal women who are already vulnerable to bone loss.  Some research suggests the mechanics of GLP-1 agonists may actually protect bone loss in reducing diabetes complications, however, it is the rapid weight loss, combined with loss of lean body mass (muscle) that poses a greater concern for bone health and it important for maintaining weight loss.

What Are GLP-1 Agonists and How Do They Work?

GLP-1 agonists work by mimicking the action of the GLP-1 hormone, which helps regulate blood sugar, suppress appetite, and slow gastric emptying. Their mechanism is multifaceted: they increase insulin secretion in response to food intake, slow down gastric emptying, and reduce glucagon release, which helps lower blood sugar levels and may also improve fatty liver. Importantly, these drugs also target the brain’s appetite regulation centres, leading to reduced hunger and increased satiety. This makes them particularly effective for weight loss, as they address both metabolic control and the psychological aspects of eating.

However, rapid and significant weight loss is known to impact bone health, raising concerns about how GLP-1 agonists and other weight-loss medications could influence bone density in menopausal women.

How Do GLP-1 Agonists Affect Bone Density?

The relationship between GLP-1 agonists and bone health is still being explored, but current evidence suggests that weight loss itself – especially rapid or significant loss – can lead to a reduction in bone density. Here’s how GLP-1 agonists may affect bones:

1. • Bone Resorption and Formation: While GLP-1 agonists have been shown to potentially slightly reduce bone resorption, this effect may be outweighed by the consequences of rapid weight loss, which decreases the mechanical load on bones, leading to bone mass reduction. This is particularly concerning in menopausal women, where the rate of bone loss is already elevated due to reduced estrogen levels.

• • Loss of Lean Body Mass: GLP-1 agonists, by promoting rapid weight loss, may also lead to a reduction in lean body mass, including muscle and bone mass. Since bones respond to the stress placed upon them, a decrease in body weight and muscle mass can result in weaker bones, increasing the risk of fractures.

• • Calcium and Vitamin D Deficiency: Weight-loss medications may also impair the absorption of essential nutrients like calcium and vitamin D, which are critical for bone health. Inadequate intake or absorption of these nutrients can accelerate bone loss, especially in menopausal women who already have higher calcium needs.

Why Is Bone Health at Greater Risk in Menopausal Women?

Menopausal women are particularly vulnerable to bone density loss due to the sharp decline in estrogen, a hormone that plays a protective role in maintaining bone strength. Estrogen helps regulate the balance between bone resorption and bone formation, and without it, bone resorption tends to outpace new bone growth. This accelerates the loss of bone density, increasing the risk of fractures, particularly in the spine, hips, and wrists.

The use of weight-loss medications that promote rapid or significant weight loss may exacerbate this risk by:

• • Reducing the mechanical load on bones: When body weight decreases, the bones experience less mechanical stress, which can lead to reduced bone formation.

• • Altering nutrient absorption: Some weight-loss medications impair the absorption of key nutrients like calcium and vitamin D, both of which are vital for bone health.

• • Reducing muscle mass: Many weight-loss medications can lead to the loss of lean muscle, further decreasing the support for bone structure and increasing fracture risk.

Strategies for Protecting Bone Health During Weight Loss

For menopausal women considering or currently using weight-loss medications like GLP-1 agonists, it’s essential to take proactive steps to protect bone health. Here are a few strategies:

1. Ensure Adequate Calcium and Vitamin D Intake: A diet rich in calcium (from sources like leafy greens, nuts and seeds) and vitamin D (from sunlight exposure or supplements) is crucial, along with adequate magnesium to support vitamin D production. Consider working with a naturopath to assess your diet and assess if additional supplementation is necessary.

2. Incorporate Weight-Bearing Exercise: Regular physical activity, particularly weight-bearing exercises such as walking, resistance training, or yoga, can help maintain and even improve bone density. These activities stimulate bone formation and strengthen muscles that support bone health. They also help maintain muscle, which is important for sustaining weight loss after discontinuing weight-loss medications.    A study published in June 2024 showed women taking GLP-1 agonists in combination with exercise had less bone loss that compared to those taking GLP-1 agonists and not exercising.  The exercise group also has additional weight loss.

3. Monitor Bone Density: If you are using weight-loss medications and are at risk for osteoporosis, it’s important to regularly monitor your bone density through scans (DEXA scans) to track any changes over time.

4. Maintain a Balanced Diet: Ensure your diet is not only focused on weight loss but also supports overall health, particularly bone health. This includes a variety of nutrients such as magnesium, phosphorus, boron, and vitamin K, all of which play roles in bone strength.

5. Consult with naturopath : If you’re concerned about the potential effects of weight-loss medications on your bone health, speak with one of the naturopaths at Elemental Health. They can guide you in making informed decisions and suggest ways to minimize bone loss and other side effects while still achieving your weight-loss goals.

GLP-1 agonists and other weight-loss medications offer significant benefits for managing weight and metabolic health, but they can also pose risks to bone density, particularly in menopausal women. As rapid weight loss and hormonal changes during menopause already compromise bone health, it’s crucial to balance the benefits of these medications with strategies that protect bone density. By adopting a nutrient-rich diet, engaging in regular physical activity, maintaining muscle and working with naturopath, menopausal women can manage their weight while safeguarding their bone health.

References:

Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial (2024)

Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies (2024)

Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists (2017)